meix and Strait,
Wouldn't it the irony of ironies if COR were to receive a much better deal now that it would have before this whole business with the hold first started? In fact, given the scope of the deals being made today, it may just have been a blessing in disguise that COR ran into all these problems with the FDA. But until we hear something definitive from the FDA, this is just all idle speculation. Nonetheless, Neuroinv and others' talk about $30 million in upfronts seems awful paltry by the most recent standards being set.
Bladerunner
Market Data 
Markets 
AI
